




Figure 1A




Figure 1B




Figure 1C




Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 4




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 8C




Figure 9A




Figure 9B




Figure 9C





Figure 10A



Figures 10B




Figure 10C




Figure 11A




Figure 11B
LL2 model




Figure 11C




Figure 12A




Figure 12B

LL2-OVA





Figure 12C

A.



Group	Treatment	nmole /mouse	mg/kg
G1_Ctrl	Vehicle		
G2_ABC1930	anti-FAP-LIGHTmu1	0.75	7.25
G3_ABC727	anti-PDL1		10
G4_ABC1930 + ABC727	anti-FAP-LIGHTmu1	0.75	7.25
	anti-PDL1		10

Figure 13A




Figure 13B




Figure 13C